| 查看: 1091 | 回复: 1 | |||
[交流]
JCR一区Frontiers in Pharmacology肝病方向专题邀稿（影响因子5.988） 已有1人参与
|
|
frontiers in pharmacology, jcr药学一区、中科院大类医学二区，小类药学二区，影响因子5.988 ，citescore： 6.6 肝病方向专题：pathophysiology and pharmacological treatments associated with liver failures，https://www.frontiersin.org/rese ... with-liver-failures abstract submission deadline: 30 june 2023, manuscript submission deadline: 02 october 2023 可以与期刊协商提供相应的文章处理费豁免，欢迎各位老师同学投稿！ pathophysiology and pharmacological treatments associated with liver failures. about this research topic: acute and chronic liver failures, which represent the loss of liver function, occupy the center stage of hepatic disorders as they are connected with a variety of liver diseases including fatty liver disease, cirrhosis, viral hepatitis, hepatocellular carcinoma and hepatic encephalopathy. the clinical manifestations of liver failures are multifaceted and usually include fatigue, diarrhea, confusion, excess bleeding, and eventually death. in many cases, the only curative treatment option is liver transplantation. although it is generally accepted that liver failures occur under the influence of miscellaneous factors, the detailed molecular mechanisms of various liver failures and associated diseases have not been fully elucidated. since acute and chronic liver failures are major causes of morbidity and mortality globally, a detailed understanding of their associated pathogenesis is essential to improve the treatment options and outcomes in the context of limited liver transplantation. currently, severe toxic, metabolic, viral, and autoimmune injuries are the mainstream theories regarding the causes of acute and chronic liver failures. reducing and limiting the influence of relevant precipitating factors, thus, are the main strategies for the treatment of liver failure-associated disorders. over the last decade, there is also emerging evidence indicating the contribution of aging, mitochondrial damage, cellular senescence, and autophagy inhibition in the development of liver failures. this research topic will try to shed light on novel research elucidating the molecular and cellular pathogenesis of various liver diseases, as well as relevant intervention strategies. the aim is to bring together the latest findings on the pathogenesis mechanisms of liver failure-associated diseases and to propose future treatment strategies for acute and chronic liver failures. the topic editors encourage researchers to submit original researches, brief research reports, systematic reviews, reviews, mini-reviews, and clinical trials relevant to the pathogenesis and management of liver diseases, including, but not limited to the following themes: 1. pathophysiology, pharmacology and intervention strategies of acute and chronic liver failures. 2. pathophysiology, pharmacology and intervention strategies of fatty liver diseases. 3. pathophysiology, pharmacology and intervention strategies of hepatocellular carcinoma. 4. pathophysiology, pharmacology and intervention strategies of liver disease-associated neurological complications. why publish in our research topic? alongside a top group of authors, your work will be published in frontiers in pharmacology, a leading journal in the field with a journal impact factor of 5.988 and a citescore of 6.6. you can read more about the collection here: https://www.frontiersin.org/rese ... with-liver-failures please click the link to register your interest in submitting an article. we accept original researches, brief research reports, systematic reviews, reviews, mini-reviews, and clinical trials. the deadline for submission is 02/10/2023, but frontiers’ fast-track review process, led by my editorial team, means each article is published online as soon as it’s been successfully peer-reviewed and accepted (typically within 61 days). as an open access journal, publishing fees are applied to accepted articles. please contact pharmacology.submissions@frontiersin.org to discuss fees, institutional waivers, and discounts. the team at frontiers will be in touch over the next few days to explain more about contributing to the collection. if you have any other questions in the meantime, please let me know. i believe your insight will be a great addition to this topic, and i look forward to hearing more about your latest research. |
回复此楼» 猜你喜欢
求助电子版：晶型药物研发理论与应用
已经有0人回复
-
祈福面上能中
已经有141人回复
-
药理学论文润色/翻译怎么收费?
已经有150人回复
-
北京大学药学院诚招药物化学/有机化学方向博士后
已经有6人回复
-
2027药学博士申请
已经有1人回复
-
求Endnote官网关于《Avian Conservation and Ecology》杂志的.ens文件
已经有2人回复
-
BL21（DE3）出现粗长丝状物
已经有0人回复
-
亚甲基引入
已经有2人回复
-
高温加热及反应瓶材质选型
已经有1人回复
-
【2027申博自荐】9篇SCI+国奖 | 水凝胶/纳米酶/生物材料 | 求博导带走
已经有1人回复
2楼2023-05-10 20:00:09
200